神经调控领域自主突破！医疗器械ETF逆势上涨

Core Viewpoint - The A-share market experienced a collective decline, with the Shanghai Composite Index down 0.44%, Shenzhen Component Index down 0.84%, and ChiNext Index down 1.04. The medical device ETF showed resilience, increasing by 1.00% amid mixed performances from constituent stocks, highlighting potential growth in the medical device sector driven by regulatory approvals and market trends [1]. Group 1: Market Performance - The medical device ETF (562600) rose by 1.00%, with the latest price at 0.91 yuan and a trading volume of 0.14 billion yuan, reflecting a turnover rate of 6.14% [1]. - The medical device ETF has seen a scale increase of 0.42 billion yuan over the past week, reaching a new high since its launch [2]. - The medical device ETF has recorded net inflows for six consecutive trading days, with a maximum single-day net inflow of 0.15 billion yuan, totaling 0.48 billion yuan in net inflows [2]. Group 2: Company Developments - Lepu Medical's subsidiary received regulatory approval for a rechargeable implantable deep brain stimulation (DBS) system, marking a significant breakthrough in China's neuroregulation field and expected to enhance performance while mitigating the impact of centralized procurement [1]. - The global DBS market is anticipated to grow rapidly, with an increasing trend towards alternatives [1]. Group 3: Valuation and Sector Composition - The latest price-to-earnings ratio (PE-TTM) for the medical device ETF is 47.48, which is below the 63.83% percentile of the past decade, indicating a moderate valuation [2]. - The ETF's index weight is heavily concentrated in the pharmaceutical and biological sectors (95.14%), with smaller allocations to beauty care (4.60%) and light manufacturing (0.26%) [2]. - Within the secondary industry classification, the ETF's index weight is primarily in medical devices (90.28%), followed by medical services (4.36%) and medical beauty (3.30%) [2].